The DNA methylome in panic disorder: a case-control and longitudinal psychotherapy-epigenetic study

Christiane Ziegler1, Franziska Grundner-Culemann2, Miriam A. Schiele1, Pascal Schlosser2, Leonie Kollert3, Marina Mahr3, Agnieszka Gajewska3, Klaus-Peter Lesch4,5,6, Jürgen Deckert3, Anna Köttgen2 and Katharina Domschke1,7

Abstract
In panic disorder (PD), epigenetic mechanisms such as DNA methylation of candidate genes have been suggested to play a key role at the intersection of genetic and environmental factors. On an epigenome-wide level, however, only two studies in PD patients have been published so far, while to date no study has intra-individually analyzed dynamic epigenetic correlates of treatment-response in PD on a DNA methylome level. Here, an epigenome-wide association study (EWAS) was performed in a sample of 57 PD patients and matched healthy controls using the Illumina MethylationEPIC BeadChip, along with a longitudinal approach assessing changes on the DNA methylome level corresponding to clinical effects of a manualized six-week cognitive-behavioral therapy (CBT) in PD. While no epigenome-wide significant hits could be discerned, top suggestive evidence was observed for decreased methylation in PD at cg19917903 in the Cilia and Flagella Associated Protein 46 (CFAP46) gene, and for an increase in methylation after CBT at cg06943668 in the Interleukin 1 Receptor Type 1 (IL1R1) gene in treatment responders to CBT. Additional exploratory analyses based on biological validity and a combined statistical/biological ranking point to further new potential PD risk genes such as the CCL4L1 or GMNN genes, and suggest dynamic methylation of, e.g., the ZFP622 and the SLC43A2 genes along with response to CBT. These EWAS and first longitudinal epigenome-wide pilot data in PD add to the emerging candidate gene-based body of evidence for epigenetic mechanisms to be involved in PD pathogenesis and to possibly constitute dynamic biological correlates of therapeutic interventions.

Introduction
Panic disorder (PD) is a frequent and highly debilitating mental disorder with a life-time prevalence of 1–3% and women being affected ~2–3 times more often than men1. The pathomechanism of PD is complex involving interactions between environmental influences, psychological mechanisms and genetic factors amounting to an estimated heritability of 48%2. While cognitive-behavioral therapy (CBT) and pharmacotherapy are very effective for most patients with anxiety disorders, 20–40% of patients with PD suffer from treatment resistance along with a lower socioeconomic status, poorer quality of life and an increased rate of of suicidal attempts3.

In anxiety, affective and stress-related disorders, epigenetic mechanisms such as DNA methylation have been suggested to play a key role at the intersection of genetic and environmental factors in disease pathogenesis as well as in treatment response mediation (see refs. 4,5). Specifically for PD, there is preliminary evidence for differential DNA methylation of several candidate genes—i.e., the
norepinephrine transporter (SLC6A2, NET)\(^6\), the monoamine oxidase A (MAOA)\(^7,8\), the glutamate decarboxylase 1 (GAD1)\(^9\), the corticotropin releasing hormone receptor 1 (CRHRI)\(^10\) and the forkhead-box-protein P3 gene (FOXP3)\(^11\)—to be involved in disease pathology (for review see refs. \(^5,12,13\)). On the methylymome level, two recent epigenome-wide association studies (EWAS) in PD using the Infinium HumanMethylation450 BeadChip have suggested hypermethylation of a CpG site in the enhancer region of the homo sapiens headcase homolog (Drosophila) (HECA) gene in 49 European PD patients and an independent replication sample\(^14\), and mostly hypomethylation at 40 CpG sites, in 48 Japanese patients with PD as compared to healthy controls\(^15\). Finally, in a proof-of-principle, candidate gene-based treatment-epigenetic approach, MAOA hypomethylation in patients with PD has been observed to be reversible by a successful cognitive-behavioral psychotherapeutic intervention in two independent samples, with responders showing an increase in MAOA methylation after treatment, i.e., ‘normalization’ up to methylation levels in healthy controls\(^6,8\). To the best of our knowledge, a longitudinal study on epigenetic correlates of treatment-response in PD on the DNA methylome level has not been published so far.

Thus, in the present study we set out (1) to perform an EWAS in a PD case-control design using the Illumina MethylationEPIC BeadChip covering >90% of the original CpGs contained in the HumanMethylation450 BeadChip as utilized in previous PD EWAS\(^14,15\) plus an additional \(~350,000\) CpGs, and (2) to analyze changes on the DNA methylome level along with clinical effects of a six-week CBT in PD for the first time in a longitudinal design. These hypothesis-generating approaches are expected to allow for identification of yet unidentified differential DNA methylation in PD, and to potentially reveal epigenetic mechanisms of action of therapeutic interventions based on fear extinction thereby informing clinicians’ treatment decisions towards a more individualized therapy in anxiety disorders.

**Patients and methods**

**Samples**

Fifty-seven PD patients were recruited at the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Germany, within project C02 of the Collaborative Research Center SFB-TRR-58 ‘Fear, Anxiety, Anxiety Disorders’ funded by the German Research Foundation. Caucasian background of all participants was ascertained for at least two preceding generations. PD diagnosis was made on the basis of a structured clinical interview (SCID-I) by experienced psychiatrists and/or clinical psychologists. Apart from bipolar disorder, psychotic disorders, current alcohol dependence, current abuse or dependence on benzodiazepines and other psychoactive substances, comorbid axis I diagnoses were allowed if PD was the primary diagnosis (for details see Table 1). Current or previous severe internal or neurological somatic illnesses, pregnancy, excessive alcohol (>15 glasses of alcohol per week) or nicotine (>20 cigarettes per day) consumption and illegal drugs including cannabis (assessed by urine toxicology) were exclusion criteria.

A control group of 61 healthy subjects matched to the patient group by age, smoking status and number of smoked cigarettes per day was recruited at the Department of Psychiatry, Psychosomatics and Psychotherapy,

Table 1 Sample characteristics.

| Characteristics | PD patient group (\(N = 57\)) | Control group (\(N = 61\)) | Statistics |
|-----------------|-------------------------------|-----------------------------|------------|
| Gender distribution | 43 vs 14 vs males | 47 vs 14 vs males | \(X^2 = 0.042, p = 0.837\) |
| Age in years (mean ± SD) | 33.96 ± 9.71 vs 33.25 ± 9.18 | | \(t = 0.162, p = 0.872\) |
| Comorbidities (yes vs no): | | | |
| Agoraphobia | 26 vs 31 vs n.a. vs n.a. | | |
| Social anxiety disorder | 3 vs 54 vs n.a. vs n.a. | | |
| Specific phobias | 2 vs 55 vs n.a. vs n.a. | | |
| Smoking status (smokers vs non-smokers) | 18 vs 39 vs 17 vs 44 | | \(X^2 = 0.041, p = 0.839\) |
| Smoked cigarettes, per day (mean ± SD) | 12.17 ± 6.05 vs 9.56 ± 5.68 | | \(t = −1.288, p = 0.207\) |
| Psychiatric medication (yes vs no) | | | |
| SSRIs | 16 vs 41 vs n.a. vs n.a. | | |
| SNRs | 5 vs 52 vs n.a. vs n.a. | | |
| NaSSA | 6 vs 51 vs n.a. vs n.a. | | |
| TCA | 7 vs 50 vs n.a. vs n.a. | | |
| Pregabalin | 2 vs 55 vs n.a. vs n.a. | | |
| Antipsychotics | 2 vs 55 vs n.a. vs n.a. | | |
| Zopiclone | 1 vs 56 vs n.a. vs n.a. | | |
| Benzodiazepines | 1 vs 56 vs n.a. vs n.a. | | |

Sample characteristics are shown for the panic disorder (PD) patient group and the healthy control group. Between-group comparisons were carried out by Chi-square tests for categorical data or Students t-tests for categorical data. n.a. not applicable. SSRIs selective serotonin re-uptake inhibitors, SNRs selective serotonin and norepinephrine re-uptake inhibitors, NaSSA noradrenaline and selective serotonin agonists, TCA tricyclic antidepressants

*Psychiatric medication at baseline

\(^{a}\)No patient received any other psychoactive medication, and medication remained unmodified during the course of cognitive-behavioral therapy (see section ‘Treatment’).

---

\(^{6}\)the glutamate decarboxylase 1 (GAD1)

\(^{9}\)the corticotropin releasing hormone receptor 1 (CRHRI)

\(^{10}\)the forkhead-box-protein P3 gene (FOXP3)

\(^{11}\)to be involved in disease pathology (for review see refs. \(^5,12,13\))

\(^{14}\)recent epigenome-wide association studies (EWAS) in PD using the Infinium HumanMethylation450 BeadChip

\(^{15}\)independent replication sample
University of Wuerzburg, Germany. Current and/or lifetime mental axis I disorder were excluded by experienced psychologists based on the Mini International Neuropsychiatric Interview (MINI) according to DSM-IV criteria. Exclusion criteria corresponded to those applied to the patient sample as listed above. For detailed sample characteristics as well as between-group comparisons please refer to Table 1.

This study was approved by the ethical committee of the University of Wuerzburg, Germany, and conformed to the ethical principles of the Helsinki Declaration. Written informed consent was obtained from all participants.

**Treatment**

All 57 PD patients were treated for approximately six weeks in an outpatient clinical setting with six semi-standardized sessions according to a shortened version of the exposure-based CBT manual as applied in the ‘Mechanisms of Action for CBT’ (MAC) study within the network ‘Improving the Treatment of Panic Disorder’ funded by the German Federal Ministry of Education and Research (BMBF)8,16. Data from 51 patients having finished treatment were available for intra-individual longitudinal analyses. Psychotherapy was delivered by experienced graduate or clinical psychologists after having accomplished a training workshop on this manual. Therapists were involved in weekly supervision during the course of the study to ensure therapy integrity. The first three sessions lasting ~90 min each were conducted within 2 to 3 weeks and covered psychoeducational information (e.g., physiological, mental and behavioral components of anxiety, vicious circle of anxiety, vulnerability-stress model). The subsequent block of three sessions within the remaining 3–4 weeks comprised interoceptive exercises (e.g., hyperventilation, straw breathing, running). Exposure exercise sessions (100–240 min per session) were conducted approximately once a week and were accompanied by individualized homework. A concluding session focused on therapeutic gains, individual plans for continued exposure exercises and relapse prevention. Medication (N = 31 patients; see Table 1) had to be stable for at least two weeks before inclusion into the study and remained unchanged throughout the course of the study. Also, the quantity of smoked cigarettes was kept constant during the course of therapy.

As the primary indicator of disease severity and treatment response, respectively, the clinician-rated Hamilton Anxiety Rating Scale (HAM-A)17 was ascertained before (T0) and after (T1) therapy. Data on HAM-A score at T0 and T1 were available for 47 patients. Patients showing at least 50% reduction in HAM-A score (T1-T0) were defined as responders (N = 20), all other patients were defined as non-responders (N = 27). There was no difference regarding sex, age, smoking behavior, comorbidity with agoraphobia, depression, social anxiety disorder and specific phobias between responders and non-responders (data not shown; all p > .05).

**Blood sampling**

In the patient sample, EDTA blood was sampled at baseline (T0) and after treatment (T1). In healthy controls, EDTA blood was collected at T0 for the case-control comparison. DNA was isolated using the FlexiGene DNA Kit (QIAGEN, Hilden, Germany) and stored at −80 °C until further processing. In addition, EDTA blood was analyzed for individual differential blood cell count at the Centre of Laboratory Medicine, University of Wuerzburg, Germany.

**DNA methylation analyses**

Aliquots of genomic DNA (250 ng) were treated with sodium bisulfite by means of the EZ-96 DNA Methylation Kit (ZymoResearch, Freiburg, Germany). The Infinium MethylationEPIC Kit was used to quantify DNA methylation at ~865,000 sites (Illumina, San Diego, USA). Hybridization and processing were performed according to the manufacturer’s instructions at the Genome Analysis Centre (GAC), Helmholtz Zentrum München GmbH, Munich, Germany.

**Quality control and preprocessing of DNA methylation data**

For processing and quality control of the raw methylation data, a customized version of the CPACOR pipeline18 was used for quality control, data normalization and calculation of relative DNA methylation values, calculating principal components of the control probes for adjustment and exclusion of outliers based on the Inter-Quartile-Range. The threshold for the sample call rate was set to 0.93. White blood cell type (WBC) subpopulations were estimated based on 100 CpG sites by the Houseman method19 as implemented in the minfi R package20. Comparison of estimated and measured white blood cell sub-subpopulations in 61 patients and 65 controls showed high concordance, and therefore estimated WBC counts were used for adjustment due to completeness. One sample discordant for reported and estimated sex, based on CpGs on the X- and Y-chromosome, was excluded from analyses. Additionally, quality control based on principal component analyses of the control probes was conducted to detect samples with measurement failures. The complete preprocessing pipeline is available on github (https://github.com/genepfreiburg/Infinium-preprocessing).

In total, DNA methylation data from 56 PD patients and 60 controls were available for analysis after data preprocessing and quality control, including 56 matched
case-control pairs and 47 patients with multiple measures to study changes in DNA methylation and treatment response quantified via the HAM-A.

**Epigenome-wide association analyses**

EWAS was carried out using linear regression models and t-tests. The first three principal components of the control probes and estimated WBC counts for six cell types (CD8 T cells, CD4 T cells, natural killer cells, B-cells, monocytes, granulocytes) were used in a linear regression as predictors to adjust the relative DNA methylation values for technical biases and white blood cell composition. Using two-sided t-tests the mean of these adjusted DNA methylation values (β-values) was compared at each CpG site between matched cases and controls as well as pre- and post-therapy. Analyses evaluating change in DNA methylation during CBT were stratified according to HAM-A responder status (27 responders, 20 non-responders; see “Treatment” above).

Statistical significance was defined as $p < 5.77 \times 10^{-8}$, corresponding to a Bonferroni correction for the 865,859 evaluated CpG sites (0.05/865,859). Associations were reported as suggestive if $p < 1 \times 10^{-5}$. Inflation was assessed by the genomic inflation factor lambda and visual inspection of QQ-plots (see Supplementary Fig. S1). All CpG sites overlapping with single nucleotide polymorphisms (distance to SNP ≤ 5 bp; European ancestry based minor allele frequency ≥ 0.01) were excluded post hoc.

Additionally, given that associated CpG sites do not always have large biological effects, i.e. statistically significantly associated sites might show only very small absolute methylation differences between case and control subjects ($\Delta \beta$), CpG sites with highest methylation differences are reported to account for the biological impact of differentially methylated CpG sites. Furthermore, “statistical validity” ($p$-values) and “biological validity” (mean[Δβ]) were used to calculate “combined ranks” according to Dempster et al. In this effort, all analyzed CpG sites were ranked according to their respective $p$-value and according to their difference in methylation between groups or time points, respectively. The combined rank was then constructed from the sum of these two ranks. Ties in the combined rank were resolved by prioritization of the statistical ranking.

Pathway analyses were conducted for all CpG sites with $p < 1 \times 10^{-4}$. GO terms and KEGG pathways were tested for enrichment accounting for the number of CpG sites per gene as implemented in the missMethyl R package. Correction for multiple testing accounted for the 22,633 GO terms and 333 KEGG pathways, respectively, using the method of Benjamini and Hochberg (FDR < 0.05).

**Results**

**Case-control analysis**

Epigenome-wide case-control association analyses did not reveal epigenome-wide significant hits (see Fig. 1). However, top suggestive evidence was discerned for decreased methylation in PD patients as compared to healthy controls at cg19917903 in the gene coding for the Cilia and Flagella Associated Protein 46 (CFAP46) (see Table 2 for all four hits with $p < 1 \times 10^{-5}$).

When focusing on the “biological validity” (for details, see Methods section), the top-ranked CpG regarding difference in methylation between cases and controls was cg04850148 located within the intronic region of the C-C motif chemokine ligand 4 like 1 gene (CCL4L1) (see Supplementary Table S1 for top ten hits).

When combinedly sorting for statistical as well as biological validity considering both $p$-values and Δβ values, the top-ranked CpG regarding differential methylation between cases and controls was cg27583138 located in the promoter region of the Geminin gene (GMNN) (see Fig. 1 Manhattan plot of the adjusted epigenome-wide panic disorder association study (EWAS) model. The x axis shows the chromosomal position, the y axis shows $p$-values of the case-control analysis on a $-\log_{10}$ scale. The horizontal line indicates the threshold for suggestive sites ($p = 1 \times 10^{-5}$).
Supplementary Table S1 for the top ten hits and Supplementary Fig. S2 for volcano plot.

Pathway analyses revealed no enrichment of GO terms or KEGG pathways in the top 54 CpG sites ($p < 1E$-$04$).

**Treatment-response analysis**

When analyzing longitudinal changes in epigenome-wide DNA methylation in the patient sample stratified for responders and non-responders to CBT, top suggestive evidence was observed for an increase in methylation from T0 to T1 at cg06943668 in the gene coding for the Interleukin 1 Receptor Type 1 (*IL1R1*) in treatment responders but not in non-responders (see Table 3 for all 18 hits with $p < 1E$-$05$ in the samples of responders and non-responders, respectively).

Additionally, when considering "biological validity", cg18441082 located in the promoter region of the Zinc Finger Protein 622 (*ZFP622*) gene was the top-ranked CpG with regard to DNA methylation changes from T0 to T1 in treatment responders, but not in non-responders (see Supplementary Table S2 for top ten hits in the samples of responders and non-responders, respectively).

When combinedly sorting for both statistical and biological validity, the first-ranked differentially methylated CpG site from pre- to post-therapy in treatment responders was cg22273830 located in the intronic region of the Solute Carrier Family 43 Member 2 (*SLC43A2*) gene, transcript variants 1 and 2 (see Supplementary Table S2 for top ten hits in the samples of responders and non-responders, respectively, and Supplementary Fig. S3 for volcano plot).

Applying pathway analyses, no enrichment was discerned in the top 116 CpG sites ($p < 1E$-$04$) of the regression analysis in responders. In non-responders, pathway analyses revealed that the top 90 CpG sites ($p < 1E$-$04$) were enriched for the KEGG pathway "viral protein interaction with cytokine and cytokine receptor" (4 of 97 genes; $p = 3E$-$05$).

**In silico functional analyses**

An online in silico analysis using BECon⁵⁵ (available at https://redgar598.shinyapps.io/BECon/, as consulted online on 8 April 2019) revealed no or only weak blood-brain methylation correlations for *IL1R1* cg06943668, the hit with the lowest $p$-value with regard to changes from T0 to T1 in CBT responders (BA 10, anterior prefrontal cortex: $r_s = 0.06$; BA 20, inferior temporal gyrus: $r_s = −0.27$; BA 7, parietal cortex: $r_s = 0.05$). The top-ranked CpG derived from case-control comparison *CFAP46* cg19917903 is not contained in the BECon database and thus could not be evaluated. Furthermore, top hits from ranking according to biological validity as well as from combined ranking were evaluated in BECon as follows: *CCL4L1* cg04850148 (BA 10, anterior prefrontal cortex: $r_s = 0.30$; BA 20, inferior temporal gyrus: $r_s = 0.09$; BA 7, parietal cortex: $r_s = 0.39$); *GMNN* cg27583138 (BA 10, anterior prefrontal cortex: $r_s = 0.01$; BA 20, inferior temporal gyrus: $r_s = −0.30$; BA 7, parietal cortex: $r_s = 0.37$), and *ZNF622* cg18441082 (BA 10, anterior prefrontal cortex: $r_s = −0.24$; BA 20, inferior temporal gyrus: $r_s = −0.46$; BA 7, parietal cortex: $r_s = 0.09$). *SLC43A2* cg22273830 is not contained in the BECon database and thus could not be evaluated. Interrogating the IMAGE-CpG database²⁶ (available at https://han-lab.org/methylation/default/imageCpG, as consulted online on 8 April 2019) revealed weak blood-brain methylation correlations for *IL1R1* cg06943668, the hit with the lowest $p$-value with regard to changes from T0 to T1 in CBT responders (BA 10, anterior prefrontal cortex: $r = 0.06$; BA 20, inferior temporal gyrus: $r = −0.27$; BA 7, parietal cortex: $r = 0.05$). The top-ranked CpG derived from case-control comparison *CFAP46* cg19917903 is not contained in the BECon database and thus could not be evaluated. Furthermore, top hits from ranking according to biological validity as well as from combined ranking were evaluated in BECon as follows: *CCL4L1* cg04850148 (BA 10, anterior prefrontal cortex: $r_s = 0.30$; BA 20, inferior temporal gyrus: $r_s = 0.09$; BA 7, parietal cortex: $r_s = 0.39$); *GMNN* cg27583138 (BA 10, anterior prefrontal cortex: $r_s = 0.01$; BA 20, inferior temporal gyrus: $r_s = −0.30$; BA 7, parietal cortex: $r_s = 0.37$), and *ZNF622* cg18441082 (BA 10, anterior prefrontal cortex: $r_s = −0.24$; BA 20, inferior temporal gyrus: $r_s = −0.46$; BA 7, parietal cortex: $r_s = 0.09$). *SLC43A2* cg22273830 is not contained in the BECon database and thus could not be evaluated.

*Table 2* Differentially methylated CpG sites with suggestive significance ($p < 1E$-$05$) in patients with panic disorder as compared to healthy controls.

| Rank | CpG site   | Nearest gene annotation | Gene name                  | $p$-value | Mean (Δβ) |
|------|------------|-------------------------|----------------------------|-----------|-----------|
| 1    | cg19917903 | *CFAP46*                | Gilia And Flagella Associated Protein 46 | 3.8E-07   | 0.012     |
| 2    | cg21708468 | *RIPK4*                 | Receptor Interacting Serine/Threonine Kinase 4 | 4.1E-06   | 0.011     |
| 3    | cg06646587 | *KDM8*                  | Lysine Demethylase 8 | 4.8E-06   | −0.012    |
| 4    | cg14208909 | *VRK2*                  | Vaccinia Related Kinase 2 | 7.5E-06   | 0.021     |

Mean (Δβ): Adjusted DNA methylation values (β values) were calculated with a linear model to account for technical differences and blood cell composition. Positive values indicate methylation in patients > methylation in healthy controls, negative values indicate methylation in patients < methylation in healthy controls.
mean\textsubscript{Brain} ± SD = 0.699 ± 0.069, mean\textsubscript{Blood} ± SD = 0.395 ± 0.209).

**Discussion**

The present study applied a hypothesis-generating EWAS approach in an effort to identify (1) yet unknown differential DNA methylation associated with PD in a case-control approach and (2) possibly mechanistically relevant DNA methylation correlates of response to CBT.

**Case-control association study**

While no significant epigenome-wide methylation differences could be detected, top suggestive evidence was discerned for differential methylation at CpG site cg19917903 in intron 25 of the Cilia and Flagella Associated Protein 46 gene (CFAP46, located on chromosome 10q26.3), with PD patients displaying lower methylation as compared to healthy controls. CFAP46 is expressed in the brain, particularly the amygdala, the anterior cingulate cortex, the frontal cortex, the basal ganglia, the hippocampus, the hypothalamus, the cerebellum and the substantia nigra\textsuperscript{27} (GTEx portal, available online at www.gtexportal.org; Human Protein Atlas, available online at www.proteinatlas.org, as consulted online on 08\textsuperscript{th} April 2019). CFAP46 is part of the central apparatus of the microtubule-based cytoskeleton of the cilium. In the brain, motile cilia are found in ependymal cells lining the ventricles and some choroid plexus cells propelling the cerebrospinal fluid, while immotile, i.e. primary cilia exist in neural stem cells, neurons and astrocytes. Neuronal primary cilia serve a variety of purposes from motility to sensing of extracellular mechanical and chemical cues as well as signal production via the generation of extracellular vesicles (for review see ref. \textsuperscript{28}). Cilia are known to be essential for neurogenesis and central nervous system development and related disorders (see refs. \textsuperscript{29–31}). A role in neuronal function related to mental disorders is suggested by studies showing elongation of primary cilia in the mouse brain in response to lithium treatment\textsuperscript{32} and a diminished primary cilia formation in

---

*Fig. 2 Manhattan plot of the adjusted epigenome-wide treatment-response association study (EWAS) model (stratified by responders and non-responders). The x axis shows the chromosomal position, the y axis shows p-values of the longitudinal analyses on a -log\textsubscript{10} scale. The horizontal line indicates the threshold for suggestive sites (p = 1E-5). a Results in the responder stratum and b in the non-responder stratum.*
Table 3 Pre- (T0) to post-therapy (T1) differentially methylated CpG sites with suggestive evidence ($p < 1E-5$) in the patients with panic disorder stratified for responders and non-responders to a six-week cognitive-behavioral therapy.

| Rank | CpG site | Nearest gene annotation | Gene name                                      | $p$-value | Mean ($\Delta\beta$) |
|------|----------|--------------------------|-----------------------------------------------|-----------|----------------------|
|      |          |                          |                                               |           |                      |
|      |          |                          | **Treatment responders**                       |           |                      |
| 1    | cg06943668 | IL1R1                    | Interleukin 1 Receptor Type 1                 | 8.0E-07   | 0.015               |
| 2    | cg22838050 | MED16                    | Mediator Complex Subunit 16                  | 1.4E-06   | 0.044               |
| 3    | cg11540895 | JPH3                     | Junctophilin 3                                | 1.4E-06   | 0.015               |
| 4    | cg09670971 | MED16                    | Mediator Complex Subunit 16                  | 2.7E-06   | 0.051               |
| 5    | cg22021794 | ESM1                     | Endothelial Cell Specific Molecule 1          | 2.9E-06   | −0.019              |
| 6    | cg13560901 | TRIL                     | TLR4 Interactor With Leucine Rich Repeats     | 3.1E-06   | 0.016               |
| 7    | cg23155853 | PDIA6                    | Protein Disulfide Isomerase Family A Member 6 | 3.2E-06   | −0.022              |
| 8    | cg03495053 | THBS2                    | Thrombospondin 2                              | 3.6E-06   | 0.034               |
| 9    | cg24130365 | PKD1L2                   | Polycystin 1 Like 2 (Gene/Pseudogene)         | 3.7E-06   | 0.023               |
| 10   | cg22738380 | SLC42A2                  | Solute Carrier Family 43 Member 2             | 4.9E-06   | 0.080               |
| 11   | cg15053890 | FGFI1                    | Fibroblast Growth Factor 1                    | 5.0E-06   | 0.030               |
| 12   | cg14085262 | CH3L1                    | Chitinase 3 Like 1                            | 5.3E-06   | −0.023              |
| 13   | cg15765251 | MED16                    | Mediator Complex Subunit 16                  | 7.4E-06   | 0.038               |
| 14   | cg09468328 | SPSB1                    | SpiA/Ryanodine Receptor Domain And SOCS Box Containing 1 | 7.8E-06 | 0.010 |
| 15   | cg27447219 | STRK24                   | Serine/Threonine Kinase 24                    | 7.9E-06   | 0.008               |
| 16   | cg09929763 | B4GALNT4                 | Beta-1,4-N-Acetyl-Galactosaminyltransferase 4 | 8.0E-06   | −0.037              |
| 17   | cg02256614 | DLGAP4                   | DLG Associated Protein 4                      | 9.1E-06   | −0.012              |
| 18   | cg25502233 | GALNT9                   | Polypeptide N-Acetylgalactosaminyltransferase 9 | 9.6E-06 | −0.020             |
|      |          |                          | **Treatment non-responders**                  |           |                      |
| 1    | cg20794208 | MIR4417                  | MicroRNA 4417                                 | 1.3E-06   | −0.049              |
| 2    | cg04003371 | FAR2                     | Fatty Acyl-CoA Reductase 2                    | 2.3E-06   | −0.032              |
| 3    | cg01128923 | WNT7B                    | Wnt Family Member 7B                          | 2.5E-06   | 0.020               |
| 4    | cg20485607 | ZNF697                   | Zinc Finger Protein 697                       | 2.8E-06   | 0.062               |
| 5    | cg17003694 | NLRP1                    | NLR Family Pyrin Domain Containing 1          | 4.3E-06   | 0.011               |
| 6    | cg24582809 | SH3BPSL                  | SH3 Binding Domain Protein S Like             | 4.4E-06   | 0.028               |
| 7    | cg03644281 | NFYA                     | Nuclear Transcription Factor Y Subunit Alpha  | 4.5E-06   | −0.056              |
| 8    | cg07134666 | ZFPS7                    | ZFPS7 Zinc Finger Protein                      | 4.6E-06   | 0.057               |
| 9    | cg04346459 | NFYA                     | Nuclear Transcription Factor Y Subunit Alpha  | 4.6E-06   | −0.066              |
| 10   | cg06068179 | AFAP1                    | Actin Filament Associated Protein 1           | 5.6E-06   | 0.059               |
| 11   | cg01641908 | LOC101927437             | Uncharacterized LOC101927437, RNA gene        | 7.2E-06   | −0.012              |
| 12   | cg15905656 | CCDC42                   | Coiled-Coil Domain Containing 42              | 9.6E-06   | 0.017               |

$\text{mean (}\Delta\beta\text{)}$: Adjusted DNA methylation values ($\beta$ values) were calculated with a linear model to account for technical differences and blood cell composition. Positive values indicate an increase in methylation from T0 to T1, negative values indicate a decrease in methylation from T0 to T1. Treatment responders and non-responders were defined according to pre- to post-therapy change in Hamilton Anxiety Rating Scale (HAM-A) scores (see “Treatment”).
schizophrenia and bipolar disorder. The present findings for the first time provide suggestive support for a potential role of cilia—and particularly of altered CFAP46 DNA methylation—in the pathogenesis of PD.

Additional exploratory analyses based on biological validity and a combined statistical/biological ranking point to further new potential PD risk genes such as the C-C motif chemokine ligand 4 like 1 gene (CCL4L1), a cytokine gene, and the GMNN gene, coding for Geminin, a DNA replication inhibitor highly conserved across species and involved in cellular proliferation and neural differentiation.

**Longitudinal psychotherapy-epigenetic study**

Analysis of DNA methylation changes on methylome level along with clinical effects of a six-week cognitive-behavioral psychotherapy in PD did not reveal a hit reaching epigenome-wide significance. However, in patients responding to CBT there was top suggestive evidence for methylation at CpG site cg06943668 in intron 1 of the Interleukin 1 Receptor Type 1 (IL1R1) gene located on chromosome 2q11.2-q12.1 to increase after treatment, which could not be observed in non-responders. IL1R1 is expressed in the brain (GTEx portal, available online at www.gtexportal.org; Human Protein Atlas available online at www.proteinatlas.org, as consulted online on 8 April 2019) and encodes a receptor for the pro-inflammatory cytokines interleukin-1 alpha (IL-1 alpha) and beta (IL-1 beta). The present finding of increasing IL1R1 methylation at cg06943668 along with treatment response—and thus, given the location of cg06943668 in intron 1, potentially decreased IL1R1 expression (cf. refs. 35,36)—is in accordance with the existing body of literature suggesting an anxiety-increasing effect of IL-1 and resilience towards anxiety in the absence of IL1R1, respectively: In the rat model, intracerebroventricular infusion of IL-1 beta showed rapid diffusion into the amygdala, a core region of anxiogenesis, and gene expression analysis after endotoxin administration revealed an increase in Il1b expression in the rat amygdala related to an increase in anxiety-like behavior in the open-field test. In patients with PD and generalized anxiety disorder, significantly elevated plasma IL-1 alpha and beta concentrations were observed as compared to healthy controls. Additionally, higher levels of IL-1 beta have predicted non-response to fluoxetine treatment in children with anxiety or depressive disorders. Reciprocally, Il1r1 knock-out mice spent significantly more time in the open arms of the elevated plus-maze than wild-type animals suggesting a decreased anxiety-like behavior in the absence of Il1r1. In a similar vein, anxiety-like behavior as determined using the open-field activity and light/dark preference tests did not develop in Il1r1 knock-out mice in response to repeated social defeat or in endothelial-specific Il1r1 knock-down mice, respectively. Finally, adenosine administration increased anxiety-like behavior along with an increase in IL-1 beta activation in the mouse brain, while Il1r1 knock-out mice were resistant to adenosine-induced anxiety-like behavior. The present findings suggest a potentially immunomodulatory effect of successful cognitive-behavioral psychotherapy in PD in terms of altered IL1R1 DNA methylation.

Additional exploratory analyses based on biological validity or a “combined rank” suggest dynamic methylation of several other genes to be potentially involved in treatment response mechanisms of PD, among them the Zinc Finger Protein 622 (ZFP622) gene and the SLC43A2 gene coding for the essential amino acid transporter LAT4, which have not been implicated in mental disorders before.

In CBT non-responders, analysis of DNA methylation changes on methylome level did not discern a hit reaching epigenome-wide significance. However, a pathway analysis revealed overlap of the CpG sites with \( p < 1E-4 \) with four of 97 genes contained in the KEGG pathway “viral protein interaction with cytokine and cytokine receptor” \( (p < 3E-5) \). This finding might point towards (neuro) immunological processes—with modulatory effects of particularly cytokines—to be involved in anxiety and possibly also non-response to CBT as previously suggested by Hou and Baldwin, which should be confirmed in future independent replication studies.

In sum, these first longitudinal epigenome-wide findings in PD add to the emerging candidate gene-based body of evidence for epigenetic mechanisms possibly constituting dynamic biological correlates of therapeutic interventions focusing on fear extinction (cf. refs. 49,50) by complementing previous studies reporting MAOA methylation levels to significantly increase along with response to CBT in PD and acrophobia, as well as dynamic serotonin transporter (S-HTT; SLC6A4) and FK506 binding protein 5 (FKBPS) gene methylation to correlate with remission status after CBT in a sample of children with mixed primary anxiety disorder diagnoses.

**Limitations**

Despite several strengths such as high clinical and demographic homogeneity of the present patient sample, strict inclusion/exclusion criteria, consideration of several potential confounders of DNA methylation alterations including control for differential WBC counts and psychotropic medication, application of a case-control as well as a longitudinal therapy-epigenetic design and using the EPIC chip for the first time in a PD sample, several limitations have to be considered when interpreting the present results. While within the range of previous EWAS in PD, the present sample size is relatively small,
particularly for subsamples stratified for gender and comorbidity (e.g., with/without agoraphobia), and potentially underpowered to detect differential DNA methylation on an epigenome-wide significance level. Thus, future studies in large independent samples using a comparable clinical design are warranted to replicate the present findings and to disentangle potentially sexually dimorphic effects or possibly differential epigenetic mechanisms of “pure” PD and agoraphobia. Given that no randomized waiting-list-controlled study design was applied, it cannot be conclusively argued that the presently observed longitudinal changes in methylation are due to psychotherapy effects only. Also, we were not able to replicate previous EWAS results emerging from a European and a Japanese sample of PD patients, which might be due to a lack of power in the present, but also in those previous pilot studies. To inform future studies on necessary sample sizes of EWAS in PD patients, we performed power analyses based on the presently observed distributions. With the same design of matched cases and controls (pre-/post-treatment samples) and an intended power of 90%, an independent discovery EWAS based on the EPIC chip would require sample sizes of 77 and 24 pairs (case-control and responder analyses, respectively) to detect the strongest association signals of the present study at a Bonferroni-adjusted significance level. Evaluating all suggestive sites in a replication analysis, the median CpG site in terms of Cohen’s d would require an independent cohort of 21 pairs each for case-control and responder analyses, respectively, to have 90% power (alpha = 0.05/#suggestive sites, one sided). Furthermore, differences in sample composition regarding comorbidities with e.g. agoraphobia or depression, somatic illness, smoking behavior or medication status could explain discrepancies across EWAS in PD. Along these lines, despite careful selection of participants and controlling for potential confounders by means of phenotype matching and adjustment for WBC estimates in regression analyses, latent confounders such as diet, physical activity or life events might have influenced the results. Finally, in human studies investigation of DNA methylation is necessarily restricted to peripheral biomaterial since relevant brain tissue cannot be obtained in vivo. Several lines of evidence emerging from both animal and human studies, however, have suggested DNA isolated from peripheral sources to partly function as a viable surrogate biomarker for central processes with a considerable correlation between methylation patterns in blood and brain tissue in rodents and rhesus monkeys as well as brain metabolism of the respective molecule as measured by positron emission tomography in humans, respectively (e.g., refs. 54–56). Also in other disorders, EWAS revealed methylation sites that translate from whole blood to target tissue (e.g., in obesity or kidney disease). However, differential DNA methylation identified in peripheral biomaterial such as blood does not allow for direct conclusions regarding methylation correlates in brain tissue, especially given that online in silico analyses using the BECon database revealed no or only weak blood-brain methylation correlations for the presently top-ranked hits, which, however, does not necessarily extend to brain regions relevant for anxiety and fear such as the amygdala, the BNST, the anterior cingulate cortex or the insula.

Conclusion

In summary, the present EWAS—despite not revealing significant hits—suggests differential CFAP46 methylation to possibly be involved in PD pathogenesis, and IL1R1 methylation changes to constitute a potential mechanistic correlate of response to CBT in PD. Provided validation in larger independent samples and functional characterization of their biological relevance these findings might foster further investigation into these epigenetic signatures as potential markers of disease risk or—given the present finding of IL1R1 methylation changes in treatment responders and potential modulatory epigenetic effects in cytokine-related pathways in non-responders—immuno-modulatory pharmacological options in treatment-resistant PD for lasting treatment effects (cf. ref. 59).

Acknowledgements

The present project was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project number 44541416 – TRR 58 “Fear, Anxiety, Anxiety Disorders”, projects C02 (to K.D., K.P.L., and J.D.), Z02 (to J.D. and K.D.), A01 and A05 (to K.P.L.), as well as the German Ministry of Research and Education (BMBF, 01EO1402A, PROTECT-AD, P5 to K.D. and J.D.). The work of P.S., F.G.C., and A.K. was supported by CRC 992 (Medical Epigenetics) of the German Research Foundation (DFG), and by DFG KO 3598/3–1 and 3598/5–1 (A.K. only). Role of funding source: The funding organizations had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript. We gratefully acknowledge the skilful technical support by Carola Gagel.

Author details

1Department of Psychiatry and Psychotherapy, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 2Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center – University of Freiburg, Freiburg, Germany. 3Department of Psychology, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany. 4Division of Molecular Psychiatry, Center of Mental Health, University of Würzburg, Würzburg, Germany. 5Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. 6Department of Neuroscience, School for Mental Health and Neuroscience (MMeNS), Maastricht University, Maastricht, The Netherlands. 7Center for Basics in NeuroModulation, Faculty of Medicine, University of Freiburg, Freiburg, Germany

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
54. Provençal, N. et al. The signature of maternal rearing in the methylome in rhesus macaque prefrontal cortex and T cells. *J. Neurosci.* **32**, 15626–15642 (2012).
55. Wang, D. et al. Peripheral SLC6A4 DNA methylation is associated with in vivo measures of human brain serotonin synthesis and childhood physical aggression. *PLoS ONE* **7**, e39501 (2012).
56. Ursini, G. et al. Stress-related methylation of the catechol-O-methyltransferase Val158 allele predicts human prefrontal cognition and activity. *J. Neurosci.* **31**, 6692–6698 (2011).
57. Wahl, S. et al. Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. *Nature* **541**, 81–86 (2017).
58. Chu, A. Y. et al. Epigenome-wide association studies identify DNA methylation associated with kidney function. *Nat. Commun.* **8**, 1286 (2017).
59. Michopoulos, V., Powers, A., Gillespie, C. F., Ressler, K. J. & Jovanovic, T. Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond. *Neuropsychopharmacology* **42**, 254–270 (2017).